File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome

TitleThe neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome
Authors
Issue Date2014
Citation
Journal of Infectious Diseases, 2014, v. 209 n. 9, p. 1343-53 How to Cite?
AbstractBackground. High mortality and uncertainty about the effectiveness of neuraminidase inhibitors (NAIs) in humans infected with influenza A(H7N9) viruses are public health concerns.Methods. Susceptibility of N9 viruses to NAIs was determined in a fluorescence-based assay. The NAI oseltamivir (5, 20, or 80 mg/kg/day) was administered to BALB/c mice twice daily starting 24, 48, or 72 hours after A/Anhui/1/2013 (H7N9) virus challenge.Results. All 12 avian N9 and 3 human H7N9 influenza viruses tested were susceptible to NAIs. Without prior adaptation, A/Anhui/1/2013 (H7N9) caused lethal infection in mice that was restricted to the respiratory tract and resulted in pulmonary edema and acute lung injury with hyaline membrane formation, leading to decreased oxygenation, all characteristics of human acute respiratory distress syndrome. Oseltamivir at 20 and 80 mg/kg protected 80% and 88% of mice when initiated after 24 hours, and the efficacy decreased to 70% and 60%, respectively, when treatment was delayed by 48 hours. Emergence of oseltamivir-resistant variants was not detected.Conclusions. H7N9 viruses are comparable to currently circulating influenza A viruses in susceptibility to NAIs. Based on these animal studies, early treatment is associated with improved outcomes.
Persistent Identifierhttp://hdl.handle.net/10722/205476
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBaranovich, Ten_US
dc.contributor.authorBurnham, AJen_US
dc.contributor.authorMarathe, BMen_US
dc.contributor.authorArmstrong, Jen_US
dc.contributor.authorGuan, Yen_US
dc.contributor.authorShu, Yen_US
dc.contributor.authorPeiris, JSMen_US
dc.contributor.authorWebby, RJen_US
dc.contributor.authorWebster, RGen_US
dc.contributor.authorGovorkova, EAen_US
dc.date.accessioned2014-09-20T02:36:21Z-
dc.date.available2014-09-20T02:36:21Z-
dc.date.issued2014en_US
dc.identifier.citationJournal of Infectious Diseases, 2014, v. 209 n. 9, p. 1343-53en_US
dc.identifier.urihttp://hdl.handle.net/10722/205476-
dc.description.abstractBackground. High mortality and uncertainty about the effectiveness of neuraminidase inhibitors (NAIs) in humans infected with influenza A(H7N9) viruses are public health concerns.Methods. Susceptibility of N9 viruses to NAIs was determined in a fluorescence-based assay. The NAI oseltamivir (5, 20, or 80 mg/kg/day) was administered to BALB/c mice twice daily starting 24, 48, or 72 hours after A/Anhui/1/2013 (H7N9) virus challenge.Results. All 12 avian N9 and 3 human H7N9 influenza viruses tested were susceptible to NAIs. Without prior adaptation, A/Anhui/1/2013 (H7N9) caused lethal infection in mice that was restricted to the respiratory tract and resulted in pulmonary edema and acute lung injury with hyaline membrane formation, leading to decreased oxygenation, all characteristics of human acute respiratory distress syndrome. Oseltamivir at 20 and 80 mg/kg protected 80% and 88% of mice when initiated after 24 hours, and the efficacy decreased to 70% and 60%, respectively, when treatment was delayed by 48 hours. Emergence of oseltamivir-resistant variants was not detected.Conclusions. H7N9 viruses are comparable to currently circulating influenza A viruses in susceptibility to NAIs. Based on these animal studies, early treatment is associated with improved outcomes.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Infectious Diseasesen_US
dc.titleThe neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndromeen_US
dc.typeArticleen_US
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hken_US
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_US
dc.identifier.authorityGuan, Y=rp00397en_US
dc.identifier.authorityPeiris, JSM=rp00410en_US
dc.identifier.doi10.1093/infdis/jit554en_US
dc.identifier.pmid24133191-
dc.identifier.hkuros239515en_US
dc.identifier.volume209en_US
dc.identifier.issue9en_US
dc.identifier.spage1343en_US
dc.identifier.epage53en_US
dc.identifier.isiWOS:000334689700006-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats